- Cancer Takes Tough Toll on Family Finances
- You Might Fare Better If Your Doctor Is Female, Study Finds
- CDC Launches Online ‘Heat Forecaster’ Tool as Another Summer Looms
- Biden Administration Sets Nursing Home Staffing Minimums
- Neosporin Ointment in the Nose Might Be Potent Antibiotic
- Physical Ills Often Plague People With Schizophrenia, Bipolar
- Taking Psilocybin for Depression? Relationship With Therapist Is Key
- Stick to Heimlich Maneuver Not ‘Anti-Choking’ Devices, FDA Says
- Women in the Military at Risk for Low-Weight Babies
- Repeat Blasts Can Damage Soldiers’ Brains, Study Confirms
Trulance Approved for Chronic Constipation
Trulance (plecanatide) has been approved by the U.S. Food and Drug Administration to treat persistent constipation of unknown (idiopathic) cause in adults.
Some 42 million people in the United States are affected by constipation, according to the National Institutes of Health. Once-daily Trulance is designed to stimulate the upper gastrointestinal tract to secrete fluid and “support regular bowel function,” the FDA said in a news release.
The oral drug was evaluated in two 12-week clinical studies involving a total of 1,775 adults with chronic constipation.
Diarrhea was the most common side effect. If diarrhea becomes severe, users should stop taking Trulance and contact a doctor, the FDA advised.
Trulance is produced by New York City-based Synergy Pharmaceuticals.
More information
Visit the FDA to learn more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.